These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24532678)

  • 21. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
    Kumar N; Griffiths B; Allen J
    J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
    [No Abstract]   [Full Text] [Related]  

  • 22. Raynaud's phenomenon.
    Lally EV
    Curr Opin Rheumatol; 1992 Dec; 4(6):825-36. PubMed ID: 1457277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Classification criteria of scleroderma].
    Cabane J;
    Presse Med; 2006 Dec; 35(12 Pt 2):1916-22. PubMed ID: 17159717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic importance of digital topographic assessment of Raynaud's phenomenon. A prospective study of a population of 522 patients].
    Pistorius MA; Planchon B
    J Mal Vasc; 1995; 20(1):14-20. PubMed ID: 7745354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laser doppler imaging--a new technique for quantifying microcirculatory flow in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Clark S; Campbell F; Moore T; Jayson MI; King TA; Herrick AL
    Microvasc Res; 1999 May; 57(3):284-91. PubMed ID: 10329254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Occupational Raynaud's phenomenon in a dentist: a case report].
    Tomasini M; Todaro A; Pogliaghi L
    Med Lav; 1993; 84(1):51-4. PubMed ID: 8492736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Raynaud's phenomenon].
    Ratner GL; Slutsker GE
    Khirurgiia (Mosk); 1991 Jun; (6):36-40. PubMed ID: 1770734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of fluorescence imaging technology to identify peritoneal endometriosis: a case report of new technology.
    Levey KA
    Surg Laparosc Endosc Percutan Tech; 2014 Apr; 24(2):e63-5. PubMed ID: 24686365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unilateral limited scleroderma-like changes following formation of an arteriovenous fistula.
    Roberts H; Curnow PA
    Australas J Dermatol; 2007 Feb; 48(1):37-9. PubMed ID: 17222301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of infrathermographic examination of the face and lower limbs in the differential-diagnosis of Raynaud's phenomenon caused by vibration and systemic disease.
    Kákosy T; Boczán J
    Med Lav; 1983; 74(6):499-502. PubMed ID: 6674720
    [No Abstract]   [Full Text] [Related]  

  • 35. [Analysis of Raynaud's phenomenon in systemic scleroderma: comparative study with that in vibration disease].
    Maeda M; Shikano Y; Mori S
    Nihon Hifuka Gakkai Zasshi; 1989 Nov; 99(12):1255-9. PubMed ID: 2622060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Raynaud's phenomenon and systemic diseases: immunological viewpoint].
    Lantin JP; Duc J
    Rev Med Suisse Romande; 1992 May; 112(5):401-4. PubMed ID: 1604100
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and physiological studies of Raynaud's phenomenon.
    Engelhart M
    Dan Med Bull; 1991 Dec; 38(6):458-68. PubMed ID: 1802635
    [No Abstract]   [Full Text] [Related]  

  • 40. Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma.
    Maricq HR
    Arch Dermatol; 1992 May; 128(5):630-2. PubMed ID: 1575525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.